ECJ backs Ineos over Alpharen brand

Published: 18-Feb-2011
Regulatory Finance

Says there will be no confusion with Teva’s Alpha brand


The European Court of Justice has overturned a ban on the UK’s Ineos Healthcare using its trademark Alpharen to sell certain medicines in Hungary, Latvia and Lithuania.

This dispute centres on Ineos medicines containing magnesium iron hydroxy carbonate or hydrotalcite or derivatives used in renal dialysis and treating renal diseases and kidney ailments; and phosphate binders for treating hyperphosphataemia.

Israel’s Teva Pharmaceutical Industries had originally persuaded European Union trademark regulator OHIM that there would be confusion with its ‘Alpha’ brand.

  • Companies:
  • Teva
  • INEOS Group
See more

You may also like

Media

QuintilesIMS and Teva UK win award for harmonised data analytics

Read more
This BHBIA “Excellence in Business Analytics” award also includes recognition of the advanced marketing insight programme

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Media

QuintilesIMS and Teva UK win award for harmonised data analytics

This BHBIA “Excellence in Business Analytics” award also includes recognition of the advanced marketing insight programme
Regulatory

Patent battle for Aloxi in the US

Helsinn Healthcare and Eisai fall foul of reversed court decision regarding Teva Pharmaceuticals and Aloxi patent for the US market
Finance

US Federal Trade Commission clears Teva's acquisition of Actavis Generics

Teva expects the cash and stock deal to go ahead next week
Manufacturing

Teva receives European Commission approval to acquire Allergan's generic business

Teva will divest certain overlapping molecules and integrate Allergan's UK/Ireland activities into its own operations
Finance

Teva and Takeda set up new generics joint venture in Japan

Will begin operations in the second quarter of 2016
Regulatory

Asthma – reslizumab

Acute asthma attacks can require hospitalisation or even prove fatal, but in some sufferers the standard regimen does not give adequate control
Finance

Teva accelerates its emerging markets growth strategy with the acquisition of Rimsa

Strategic move enhances Teva’s presence in Mexico, the second largest market in Latin America and a major emerging market
Subscribe now